Novavax Has Been Part Of An Analyst Upgrade


The shares of Novavax went up on Friday after the brokerage firm HC Wainwright increased the price target of the company from a sum of $207 to $317. The company’s stock previously closed at a value of $187.63, yet opened up once again at a value of $224.37. Currently, the company has a rating of buy on the stocks of the company. 

Stock Commentary on Novavax

There have been quite a few research firms that have commented on the stocks of Novavax. Zacks Investment Research has already increased the shares of the company from a rating of sell to a rating of strong buy, along with a price target of $134 in a 12th January research report.

Cantor Fitzgerald also increased the price target of the company from $248 to $338 along with a rating of overweight in a 5th February research report. B. Riley went down the same road with a price target increased from $223 to $334, along with a buy rating in a 1st February research report. Jefferies Financial Group also gave the company a rating of buy with a $200 price target.  

One investment analyst provided the company with a rating of sell, while six of them gave it a rating of buy. The company currently has a buy rating with a $217.69 price target.

The moving average price of Novavax over 50 days has been set at $225.33, while the moving average price of the company over 200 days is $15.36 billion, with a -40.19 PE ratio, and a 2.01 beta. The debt-to-equity ratio of the company has been set at 3.61, while the company also enjoys a 2.81 quick ratio.